Tamoxifen Effects on Vestibular Function and Balance in US Male Breast Cancer Patients
Reading Time: < 1 minute Introduction Breast cancer in American males, though comprising only 1% of the approximately 250,000 annual U.S. diagnoses, presents unique therapeutic challenges. Tamoxifen, a selective estrogen receptor modulator (SERM), is a cornerstone adjuvant therapy for hormone receptor-positive cases, reducing recurrence risk by up to 50% in clinical trials like the ATAC study. However, its estrogenic blockade can induce vestibular perturbations, including dizziness and gait instability, potentially exacerbating fall risk in this aging demographic—median age at diagnosis is 68 years per SEER data. This prospective cohort study evaluates Tamoxifen's influence on balance metrics in 120 American male patients, employing comprehensive assessments to...


